Innate Pharma reports €12,6M profit for 2016

Innate Pharma has reported its consolidated financial results for the year ended December 31, 2016.

The company reported net income of €12,6 million which is increase compared to net loss of €6,7 million last year.

Mondher Mahjoubi, Chief Executive Officer of Innate Pharma, said, “The Company maintained a strong financial position whilst continuing to invest and advance its portfolio of drug candidates and enters a period where it becomes eligible to further milestone payments. Looking ahead to 2017, we are confident in building on the progress seen in 2016 with the release of more clinical data in the months ahead.”